Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance
Journal of Clinical Medicine · 15.05.2026 · 15 (10) · 3803
DOI: 10.3390/jcm15103803 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.05.2026. Verfasst von Christos Damaskos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Surgery, Laiko General Hospital, 11527 Athens, Greece. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Capivasertib is a selective pan-AKT inhibitor recently approved in combination with fulvestrant for the treatment of hormone receptor-positive (HR+)/HER2- breast cancer with alterations in the PI3K/AKT pathway. The PI3K/AKT/mTOR signaling cascade represents a critical indication of endocrine resistance and tumor progression in this subtype of breast cancer. The present review summarizes current clinical data regarding the efficacy of capivasertib, either as monotherapy or in combination with other therapeutic agents and discusses emerging biomarkers and mechanisms of resistance.
Methods
A literature search of the PubMed database was conducted to identify clinical trials evaluating capivasertib in breast cancer. Studies on capivasertib as monotherapy or in combination with fulvestrant, paclitaxel, or olaparib were included.
Results
Findings from phase I–III clinical trials indicate that capivasertib in combination with fulvestrant significantly prolongs progression-free survival in patients with HR+/HER2- advanced breast cancer, particularly in tumors containing PIK3CA, AKT1, or PTEN alterations. Drug combination approaches with paclitaxel or olaparib have demonstrated additive or synergistic effects in triple-negative and DNA repair-deficient contexts, respectively. Monotherapy studies confirm effective pathway inhibition with modest clinical benefit, primarily in AKT1-mutant tumors. Translational analyses suggest that persistent mTORC1-mediated protein synthesis and compensatory signaling activation contribute to acquired resistance.
Conclusions
Capivasertib constitutes a clinically validated therapeutic approach for the inhibition of AKT signaling in breast cancer. Its efficacy is most evident when combined with endocrine therapy; however, optimization of patient selection and rational combination strategies remains necessary to overcome resistance associated with mTORC1 activation and signaling redundancy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Surgery, Laiko General Hospital, 11527 Athens, Greece.
- N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Department of Colorectal Surgery, Guys and St Thomas' Hospital, London SE1 7EH, UK.
- 4th Department of Surgery, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Chaidari, 12462 Athens, Greece.
- First Department of Propedeutic Surgery, Hippocration General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- 8th Department of Internal Medicine, Ygeia General Hospital, 15123 Athens, Greece.
ORCID-Profile: Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Eleni I Effraimidou
Zitieren
APA
Damaskos, C., Garmpis, N., Arkadopoulos, N., Michalopoulos, N. V., Garmpi, A., Papandroudis, M. P., & Effraimidou, E. I. (2026). Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance. Journal of Clinical Medicine, 15(10), 3803. https://doi.org/10.3390/jcm15103803
Vancouver
Damaskos C, Garmpis N, Arkadopoulos N, Michalopoulos NV, Garmpi A, Papandroudis MP, et al. Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance. Journal of Clinical Medicine. 2026;15(10):3803. doi:10.3390/jcm15103803
BibTeX
@article{Damaskos2026,
author = {Damaskos, Christos and Garmpis, Nikolaos and Arkadopoulos, Nikolaos and Michalopoulos, Nikolaos V and Garmpi, Anna and Papandroudis, Miltiadis-Panagiotis and Effraimidou, Eleni I},
title = {Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {10},
pages = {3803},
doi = {10.3390/jcm15103803}
}
EUVIMED